James Whelan speaks with Dr Jeremy Levin, Executive Chair of Ceryvyn Therapeutics (ASX: CYV), about investigational CYV-101 and the company’s LAM development program.
Topics include the proposed VEGF-C/D mechanism, nebulised delivery, further inhaled safety work, scientific and patient input, and disciplined investment against development stage gates.
Levin describes a potential Australian study of fewer than 20 patients, conditional on successful safety work and progression through stage gate one. Xenon MRI is one measurement approach under consideration.
CYV-101 remains investigational. Prior ophthalmology exposure does not establish the safety or effectiveness of an inhaled treatment for LAM.
Ceryvyn was formerly known as Opthea. More interviews: smallcaps.com.au.
Information only; not financial advice.
#SmallCaps #ASX #CYV #Ceryvyn #LAM
